Advanced searches left 3/3

Epo - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 28 August 2022

* If you want to update the article please login/register

Erythropoietin as an add-on Treatment for Cognitive Side-effects of Electroconvulsive Therapy

Patients with a diagnosis of major depression unipolar disorder or bipolar disorder with a current moderate to severe depressive episode presenting a score of > 17 on the Hamilton Depression Rating Scale 17-items selected for ECT therapy will be included in the trial. Patients will be recruited from Psychiatric Centers in The Mental Health Services in the Capital City of Denmark's Capital Region of Denmark and will be randomly assigned to 4 intravenous infusions of either recombinant human EPO or placebo diluted with 100 ml saline. First time at baseline, second time 3 days after ECT session 8 was completed, and the third time at a 3 month follow-up after ECT completion. After 8 ECT sessions, the neuronal substrates for potential effects of EPO on cognition are also investigated. 0. 5 SD in our previous trial was the difference in cognitive change between EPO and saline-treated groups from baseline to post-treatment. At an alpha level of p 0. 05, the investigation has been extended to explore differences in functional magnetic resonance imaging blood-oxygen dependent response in key neural networks based on previous fMRI studies from our group, in which sample sizes of 30 age and gender matched participants showed drug-related responses on task-related neural responses at a 0. 05 level. Using FMRIB Expert Analysis Tool and the 'randomize' algorithm integrated in FSL, FMRIB Software Library, resting state and task-related fMRI data will be pre-processed and analyzed.

Source link: https://clinicaltrials.gov/ct2/show/NCT03339596


Assessing Combination Hydroxyurea and Exogenous Erythropoietin in Sickle Cell Disease

Sickle cell disease is a devastating inherited hemoglobin disorder characterized by frequent episodes of pain and chronic hemolytic anemia. According to this report, patients on stable hydroxyurea therapy with subcutaneous EPO should be treated, with the intention of determining the effectiveness of EPO therapy and its effect on chronic anemia in SCD.

Source link: https://clinicaltrials.gov/ct2/show/NCT05451940


Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy

OBJECTIVES: Primary Identifyers predictive of treatment failure in patients with solid tumors treated with epoetin beta while chemotherapy patients with epoetin beta. Using epoetin beta, Evaluate hemoglobin levels from baseline to eight weeks of treatment. In the absence of disease progression or unacceptable toxicity, patients receive epoetin beta subcutaneously for a week.

Source link: https://clinicaltrials.gov/ct2/show/NCT00875004


Effect of Iron Sucrose Combined With rHuEPO on Perioperative Allogeneic Red Blood Cell Infusion in Patients Undergoing Major Non-cardiac Surgery With Cardiovascular Risk

Both anaemia and iron deficiency are risk factors for cardiovascular disease's poor prognosis in cardiovascular patients and are independent predictors of adverse cardiovascular events in the perioperative period. In addition, the risk of cardiovascular risk factors in patients undergoing major noncardiac surgery increased from 45. 5% to 48. 2% in less than five years. This paper investigates the effect of iron sucrose and rHuEPO in perioperative allogeneic red blood cell infusion in patients undergoing major non-cardiac surgery with cardiovascular risk.

Source link: https://clinicaltrials.gov/ct2/show/NCT05353348

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions